Cardiometabolic Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction
Status:
Not yet recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
Gliflozins have demonstrated a beneficial effect in terms of incident heart failure and
related events in patients with or without diabetes. The clinical trial ICARD is an
exploratory study that aims to evaluate the cardiometabolic mechanistic effects on the
myocardium of dapagliflozin in heart failure with reduced ejection fraction. Deep phenotyping
of cardiac and vascular function will be performed using MRI. Myocardial tissue
characterization will be based on MRI and FDG-PET for glucose metabolism assessment. Liver
steatosis and fibrosis will simultaneously be assessed.